You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for OTREXUP


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for OTREXUP

Average Pharmacy Cost for OTREXUP

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
OTREXUP 20 MG/0.4 ML AUTO-INJ 54436-0020-04 467.30078 ML 2025-01-22
OTREXUP 25 MG/0.4 ML AUTO-INJ 54436-0025-04 466.61833 ML 2025-01-22
OTREXUP 15 MG/0.4 ML AUTO-INJ 54436-0015-04 470.62083 ML 2025-01-22
OTREXUP 20 MG/0.4 ML AUTO-INJ 54436-0020-04 467.90042 ML 2024-12-18
OTREXUP 15 MG/0.4 ML AUTO-INJ 54436-0015-04 470.62083 ML 2024-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for OTREXUP

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
OTREXUP 15MG/0.4ML INJ Assertio Therapeutics, Inc. 54436-0015-04 4X0.4ML 321.63 2022-04-19 - 2025-06-30 FSS
OTREXUP 25MG/0.4ML INJ Assertio Therapeutics, Inc. 54436-0025-04 4X0.4ML 348.00 2023-01-01 - 2025-06-30 FSS
OTREXUP 10MG/0.4ML INJ Assertio Therapeutics, Inc. 54436-0010-04 4X0.4ML 321.63 2022-04-19 - 2025-06-30 FSS
OTREXUP 20MG/0.4ML INJ Assertio Therapeutics, Inc. 54436-0020-04 4X0.4ML 348.00 2023-01-01 - 2025-06-30 FSS
OTREXUP 15MG/0.4ML INJ Assertio Therapeutics, Inc. 54436-0015-04 4X0.4ML 348.00 2023-01-01 - 2025-06-30 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Otrexup

Introduction to Otrexup

Otrexup, a drug-device combination, is a single-dose, once-weekly auto-injector containing methotrexate, a prescription medicine. It is indicated for the treatment of severe, active rheumatoid arthritis and active polyarticular juvenile idiopathic arthritis (pJIA) in adults and children, respectively, as well as for the control of symptoms of severe, resistant, disabling psoriasis in adults[2].

Market Context

The global market for rheumatoid arthritis (RA) drugs is projected to reach $53.1 billion by 2031, growing at a CAGR of 5.6% over the forecast period. This growth is driven by the increasing number of promising RA therapies, recent drug approvals, and their rapid uptake worldwide. The market is mainly driven by premium-priced anti-TNF drugs and other targeted biologics, with JAK inhibitors also expected to contribute significantly[3].

Current Market Performance of Otrexup

As of the third quarter of 2021, Otrexup generated trailing 12-month revenues of $15.5 million. The product has a gross margin percentage in the low 70s, indicating a profitable margin for the manufacturer[2].

Acquisition and Financial Implications

In December 2021, Assertio Holdings, Inc. acquired Otrexup from Antares Pharma, Inc. for a total purchase price of $44 million, including $18 million upfront and $26 million in deferred payments. This acquisition is expected to be accretive to Assertio's adjusted EBITDA in 2022 and aligns with the company's goal of acquiring new products to deliver at least $50 million in gross profit by 2024[2].

Patent Life and Commercialization Potential

Otrexup has nearly ten years of patent life remaining, expiring in May 2031. This extended patent life provides a significant window for Assertio to invest in further commercialization and leverage its digital platform and expertise for growth[2].

Market Segments and End-Users

Indications

Otrexup is used for:

  • Severe, active rheumatoid arthritis in adults
  • Active polyarticular juvenile idiopathic arthritis (pJIA) in children
  • Control of symptoms of severe, resistant, disabling psoriasis in adults[2].

End-Users

The primary end-users of Otrexup are hospitals and specialty clinics, given the advanced facilities and high treatment costs associated with these settings[5].

Regional Outlook

Global Methotrexate Market

The global methotrexate market, which includes Otrexup, is dominated by North America due to the high prevalence of cancer, psoriasis, and arthritis, as well as the presence of key players. Europe holds the second largest market share, while the Asia Pacific region is expected to grow at the fastest pace due to its large patient pool and advancing healthcare infrastructure[5].

Price Projections and Revenue Growth

Current Pricing and Revenue

Given the trailing 12-month revenues of $15.5 million and a gross margin in the low 70s, Otrexup is a profitable product. The acquisition by Assertio is expected to enhance its commercialization efforts, potentially leading to increased revenues.

Future Growth

Assertio's strategy to leverage its digital platform and expertise is expected to drive growth for Otrexup. The company aims to achieve at least $50 million in gross profit from new product acquisitions by 2024, with Otrexup being a key contributor to this goal[2].

Market Trends

The increasing demand for effective small-molecule therapies in the RA market, coupled with the ongoing safety challenges with key classes of RA therapeutics, presents an opportunity for Otrexup to gain market share. The launch of biosimilars, however, may introduce competitive pressure, particularly in the European market[3].

Competitive Landscape

Key Players

The methotrexate market, including Otrexup, is competitive with several key players. Antares Pharma, Inc., the original developer of Otrexup, has a suite of drug injection devices that enhance patient compliance and ease of use. Other players in the RA market include those offering biologics and JAK inhibitors, which are also significant competitors[4].

Biosimilars

The expected launch of biosimilars throughout the forecast period will have a significant impact on the RA market, including the methotrexate segment. This could lead to downward pressure on prices but also presents opportunities for differentiated products like Otrexup to maintain market share through their unique delivery systems and patient compliance benefits[3].

Key Takeaways

  • Acquisition and Financials: Assertio Holdings, Inc. acquired Otrexup for $44 million, expecting it to be accretive to adjusted EBITDA in 2022.
  • Market Potential: Otrexup has significant growth potential due to its extended patent life and the growing demand for RA treatments.
  • Regional Outlook: North America and Europe are key markets, with the Asia Pacific region expected to grow rapidly.
  • Competitive Landscape: The market is competitive, with biosimilars and other RA treatments posing challenges and opportunities.
  • Price Projections: Increased commercialization efforts by Assertio are expected to drive revenue growth, though biosimilar launches may impact pricing.

FAQs

Q: What is Otrexup used for? A: Otrexup is used for the treatment of severe, active rheumatoid arthritis, active polyarticular juvenile idiopathic arthritis (pJIA), and the control of symptoms of severe, resistant, disabling psoriasis in adults.

Q: Who acquired Otrexup and for how much? A: Assertio Holdings, Inc. acquired Otrexup from Antares Pharma, Inc. for a total purchase price of $44 million.

Q: What is the current revenue and gross margin of Otrexup? A: As of the third quarter of 2021, Otrexup generated trailing 12-month revenues of $15.5 million with a gross margin in the low 70s.

Q: How long does the patent for Otrexup last? A: The patent for Otrexup is set to expire in May 2031, providing nearly ten years of exclusive market presence.

Q: What are the key drivers of the global methotrexate market? A: The global methotrexate market is driven by the increasing number of promising RA therapies, recent drug approvals, and their rapid uptake worldwide, particularly in North America and Europe.

Sources

  1. Assertio Holdings, Inc. Announces the Acquisition of Otrexup (methotrexate) a Drug Device Combination from Antares Pharma, Inc. - Biospace
  2. Assertio Holdings, Inc. Announces the Acquisition of Otrexup (methotrexate) a Drug Device Combination from Antares Pharma, Inc. - GlobeNewswire
  3. Global Rheumatoid Arthritis Drugs Market $53.1 Billion by 2031 - iHealthcareAnalyst
  4. Small-Cap Research: Antares Pharma, Inc. - Zacks Investment Research
  5. Methotrexate Market is expected to grow further with its Increasing Application in the Treatment of Cancer and Arthritis - Biospace

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.